Emerging Ideas
In the ABC-Ri GeneSis, we cultivate and nurture Emerging Ideas that hold the potential to shape the future of biomedical translational research. Our dynamic environment provides a supportive platform for researchers to explore innovative concepts aligned with the mission of ABC-Ri. With access to resources, mentorship, and collaborative opportunities, we empower researchers to develop and refine their ideas. These projects have the potential to evolve into new research groups or be integrated into existing ones, ultimately contributing to our overarching goal of advancing biomedical research and innovation.
Social determinants, in all their extension, whether economic, family or biodemographic, condition health in an important way as do genetic, aging, or environmental factors. Minority groups, as a rule, have a worse state of health and greater access difficulties, not because they have intrinsic factors but because of the conditions that surround them and the intersectionality frame in which they are inserted.
The creation of a new line of medical research in the field of LGBTQ+ health, has the mission to contributes LGBTQ+ health across the life cycle, by creating and communicating new knowledge through innovating research and by improve LGBT-related curricula, enhancing providers competencies, and reducing the health disparities in LGBTQ+ populations.
The group will be focus on two major research areas – LGBTQ+ health: clinical and epidemiological research and LGBTQ+ medical education research.
The major aim of the Pharmacotherapy and Pharmacovigilance Group is to improve human health, mainly during the ageing process, through the promotion of the use of most efficient, innovative, and safe medicines to treat, diagnose and prevent diseases. To achieve its objective, this Group has three main research lines, namely: i) to perform studies on the pharmacotherapy and medicines consumption pattern; ii) to evaluate the impact of clinical pharmacy services on the health condition of patients; and iii) to identify and analyse the main adverse drug reactions in clinical practice as well as to carry out pharmacoepidemiologic and other studies related to drug safety.